HUP0400029A2 - Obstruktív légúti megbetegedések kezelésére szolgáló adenozin A2a receptor agonista és antikolinerg hatóanyag-kombináció és ezt tartalmazó gyógyszerkészítmény - Google Patents

Obstruktív légúti megbetegedések kezelésére szolgáló adenozin A2a receptor agonista és antikolinerg hatóanyag-kombináció és ezt tartalmazó gyógyszerkészítmény

Info

Publication number
HUP0400029A2
HUP0400029A2 HU0400029A HUP0400029A HUP0400029A2 HU P0400029 A2 HUP0400029 A2 HU P0400029A2 HU 0400029 A HU0400029 A HU 0400029A HU P0400029 A HUP0400029 A HU P0400029A HU P0400029 A2 HUP0400029 A2 HU P0400029A2
Authority
HU
Hungary
Prior art keywords
adenosine
combination
pharmaceutical composition
composition containing
receptor agonist
Prior art date
Application number
HU0400029A
Other languages
English (en)
Inventor
Roisin A. Armstrong
Michael Yeadon
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0129275A external-priority patent/GB0129275D0/en
Priority claimed from GB0210238A external-priority patent/GB0210238D0/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of HUP0400029A2 publication Critical patent/HUP0400029A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU0400029A 2001-05-25 2002-05-24 Obstruktív légúti megbetegedések kezelésére szolgáló adenozin A2a receptor agonista és antikolinerg hatóanyag-kombináció és ezt tartalmazó gyógyszerkészítmény HUP0400029A2 (hu)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29384201P 2001-05-25 2001-05-25
GB0129275A GB0129275D0 (en) 2001-12-06 2001-12-06 Pharmaceutical combination
GB0210238A GB0210238D0 (en) 2002-05-03 2002-05-03 Pharmaceutical composition
PCT/EP2002/005725 WO2002096462A1 (en) 2001-05-25 2002-05-24 An adenosine a2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases

Publications (1)

Publication Number Publication Date
HUP0400029A2 true HUP0400029A2 (hu) 2004-04-28

Family

ID=27256345

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400029A HUP0400029A2 (hu) 2001-05-25 2002-05-24 Obstruktív légúti megbetegedések kezelésére szolgáló adenozin A2a receptor agonista és antikolinerg hatóanyag-kombináció és ezt tartalmazó gyógyszerkészítmény

Country Status (22)

Country Link
US (1) US20040171576A1 (hu)
EP (1) EP1395287A1 (hu)
KR (1) KR20030097901A (hu)
CN (1) CN1535161A (hu)
AP (1) AP2003002911A0 (hu)
BG (1) BG108383A (hu)
BR (1) BR0209986A (hu)
CA (1) CA2448086A1 (hu)
CO (1) CO5540324A2 (hu)
CZ (1) CZ20033126A3 (hu)
EE (1) EE200300586A (hu)
HU (1) HUP0400029A2 (hu)
IL (1) IL158774A0 (hu)
MA (1) MA27028A1 (hu)
MX (1) MXPA03010787A (hu)
NO (1) NO20035202D0 (hu)
OA (1) OA12609A (hu)
PA (1) PA8546101A1 (hu)
PL (1) PL366899A1 (hu)
SK (1) SK14302003A3 (hu)
SV (1) SV2003001055A (hu)
WO (1) WO2002096462A1 (hu)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
SG176313A1 (en) 2001-10-01 2011-12-29 Univ Virginia Patent Found 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
GB0129273D0 (en) 2001-12-06 2002-01-23 Pfizer Ltd Crystalline drug form
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
WO2006023272A1 (en) 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
CA2576826C (en) 2004-08-02 2014-09-30 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0511065D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
RU2421464C2 (ru) 2005-10-21 2011-06-20 Новартис Аг Человеческие антитела к il-13 и их терапевтическое применение
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
RU2009115954A (ru) 2006-09-29 2010-11-10 Новартис АГ (CH) Пиразолопиримидины в качестве ингибиторов липидной киназы р13к
WO2008052734A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
JP5584138B2 (ja) 2008-01-11 2014-09-03 ノバルティス アーゲー キナーゼ阻害剤としてのピリミジン類
SI2391366T1 (sl) 2009-01-29 2013-01-31 Novartis Ag Substituirani benzimidazoli za zdravljenje astrocitomov
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
AU2010283806A1 (en) 2009-08-12 2012-03-01 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
GEP201706639B (en) 2009-08-17 2017-03-27 Intellikine Llc Heterocyclic compounds and uses thereof
BR112012008061A2 (pt) 2009-08-20 2016-03-01 Novartis Ag compostos de oxima heterocíclica
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
AU2012220572A1 (en) 2011-02-25 2013-08-29 Irm Llc Compounds and compositions as trk inhibitors
US9062045B2 (en) 2011-09-15 2015-06-23 Novartis Ag Triazolopyridine compounds
JP6130391B2 (ja) 2011-11-23 2017-05-17 インテリカイン， エルエルシー Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
CN110507654A (zh) 2012-04-03 2019-11-29 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
CA2954862A1 (en) 2014-07-31 2016-02-04 Novartis Ag Combination therapy
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
ATE331726T1 (de) * 1998-10-16 2006-07-15 Pfizer Adenine-derivate
GB9924363D0 (en) * 1999-10-14 1999-12-15 Pfizer Central Res Purine derivatives

Also Published As

Publication number Publication date
PA8546101A1 (es) 2003-12-10
PL366899A1 (en) 2005-02-07
AP2003002911A0 (en) 2003-12-31
MA27028A1 (fr) 2004-12-20
BG108383A (bg) 2004-08-31
EP1395287A1 (en) 2004-03-10
EE200300586A (et) 2004-04-15
WO2002096462A1 (en) 2002-12-05
IL158774A0 (en) 2004-05-12
MXPA03010787A (es) 2004-03-02
CN1535161A (zh) 2004-10-06
KR20030097901A (ko) 2003-12-31
OA12609A (en) 2006-06-09
SV2003001055A (es) 2003-11-14
SK14302003A3 (sk) 2004-08-03
CO5540324A2 (es) 2005-07-29
CZ20033126A3 (cs) 2004-09-15
US20040171576A1 (en) 2004-09-02
NO20035202D0 (no) 2003-11-24
CA2448086A1 (en) 2002-12-05
BR0209986A (pt) 2004-04-06

Similar Documents

Publication Publication Date Title
HUP0400029A2 (hu) Obstruktív légúti megbetegedések kezelésére szolgáló adenozin A2a receptor agonista és antikolinerg hatóanyag-kombináció és ezt tartalmazó gyógyszerkészítmény
IL130424A (en) Compositions comprising ziprasidone or its hydrochloride monohydrate, their preparation and use thereof in the preparation of medicaments for treating psychosis
HUP0401191A3 (en) Opioid agonist formulations with releasable and sequestered antagonist and process for their preparation
HUP0203458A3 (en) Nociceptin receptor orl-1 agonists for use in treating cough and pharmaceutical compositions containing them
HUP0400037A2 (hu) Obstruktív légúti megbetegedések kezelésére szolgáló PDE4 inhibitor és antikolinerg hatóanyag-kombináció és ezt tartalmazó gyógyszerkészítmény
EP1210063A4 (en) COMPOSITIONS AND METHODS FOR IMPROVING THE ABSORPTION OF HYDROPHILIC THERAPEUTIC ACTIVE SUBSTANCES
ZA200503645B (en) Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds
IL231810A0 (en) History of itansinoid and pharmaceutical preparations containing them, methods for their preparation and their uses for use in cancer treatment
AP2002002392A0 (en) Indazole compounds and pharmaceutical compositions for inhibiting protein kinases and methods for their use
AU6178201A (en) Method and apparatus for diagnostic and therapeutic agent delivery
AU2003206946A8 (en) Agent for inhibiting development or progress of proliferative diseases and especially cancer diseases and pharmaceutical composition containing said agent
HUP0402270A3 (en) [1,2,4]triazolo[1,5-c]pyrimidin-5-yl-amines as adenosine a2a receptor antagonists and pharmaceutical compositions containing them
IL149495A0 (en) Pharmaceutical formulations comprising p2t receptor antagonist and anti-thrombotic agent and use thereof in therapy
IL161834A0 (en) Pharmaceutical compositions and methods for administering ep2 receptor selective agonists
EP1315672A4 (en) ADMINISTRATIVE COMPOSITION COMPOSITION AND METHOD FOR THE ADMINISTRATION OF ANTIGENES AND OTHER ACTIVE SUBSTANCES
HUP0300221A3 (en) Use of oltipraz as an antifibrotic and anticirrhotic agent in the liver for producing pharmaceutical compositions and pharmaceutical compositions containing oltipraz and process for producing them
EP1471819A4 (en) COMPOSITION AND IMAGING METHODS FOR PHARMACOKINETIC AND PHARMACODYNAMIC EVALUATION OF A THERAPEUTIC DELIVERY SYSTEM
IL153487A0 (en) Pharmaceutical compositions and methods for use
HUP0500958A3 (en) 2-arylimino-2,3-dihydrothiazole derivatives, methods for preparing them, therapeutic use thereof and pharmaceutical compositions containing them
IL153897A0 (en) Pharmaceutical compositions and methods for use
HUP0700046A2 (en) Crytalline form of a ribofuranosyluronamide derivative; a human adenosine a2a receptor agonist, manufacture use thereof and pharmaceutical composition containing thereof
HUP0204324A3 (en) Use of fsh for preparation of pharmaceutical composition suitable for treating infertility
ZA200308465B (en) An adenosine A2A receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases.
HUP0402540A3 (en) Pharmaceutical combinations of adenosine a-2a and betha-2-adrenergic receptor agonists
IL146142A0 (en) 2-substituted-5'-o-(1-boranotriphosphate adenosine derivatives and pharmaceutical compositions comprising them for treatment of type 2 diabetes

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees